article
Turning the TIDE: oligonucleotide development trends
Discover what is driving the oligonucleotide therapeutics sector as scientists navigate challenges such as financing and success-to-market.
List view / Grid view
Therapeutics
news
INTERPHEX 2023 – experience science through commercialisation
From development to distribution, leading global event Interphex 2023 (April 25-27 New York, US) takes you through all stages of the pharma product lifecycle.
news
Biogen to develop amyloid beta-targeting antibody platform
The next-generation of anti- amyloid beta therapeutics could be advanced by Biogen exercising the option to develop Denali’s antibody programme.
news
Personalised blood pressure treatment shows efficacy
A study suggests that personalised blood pressure medication can "probably obtain better protection against future cardiovascular diseases".
article
ILAP: Improving access to innovative oncology treatments
With no new first-line treatment for de-differentiated liposarcoma in over forty years, Dr Christoph Zehendner, Medical Director of Boehringer Ingelheim UK and Ireland discusses the company’s ILAP designation of its investigational, innovative treatment.
news
Microbial fermentation tech market to exceed $56.9b by 2033
Trends such as sustainability and technological advances like AI are helping to boost the microbial fermentation technology market, a report says.
news
Sustained-release chemotherapy has potential for bladder cancer
A study has shown an intravesical sustained-release chemotherapy device demonstrated effectiveness in advanced bladder cancer.
news
Eculizumab biosimilar gets positive CHMP opinion
Samsung Bioepis’ first haematology biosimilar, which references Soliris (eculizumab), has been recommended for approval by the CHMP.
news
Monoclonal antibodies can lower COVID-19 hospitalisation risk
Over a third of COVID-19 patients reduced their risk of serious outcomes when treated early with monoclonal antibodies, a study shows.
news
Treatment shows strong potential for ALK-driven neuroblastoma
A Phase I study has shown significant promise in treating newly diagnosed ALK-driven high-risk neuroblastoma in paediatric patients.
news
CHMP meeting highlights – March 2023
In the European Medicines Agency's March human medicines committee meeting, nine new medicines were recommended, including one for multiple sclerosis.
news
Generic manufacturers sign sublicences to produce long-acting HIV medicine
Sublicence agreements signed by the Medicines Patent Pool (MPP) and three generic manufacturers could enable millions to access a long-acting HIV medicine.
news
Biopharma could reap benefits from SVB UK acquisition
One of the largest banking collapses in US history could provide the biotech sector unseen opportunities, say GlobalData.
news
GSK to exclusively license novel oral antifungal
The only US Food and Drug Administration (FDA)-approved oral antifungal for vulvovaginal candidiasis will be exclusively licensed by GSK.
news
Novel delivery approach demonstrates efficacy of immunotherapy
A first-in-human study showed a novel approach for delivering intrathecal and intravenous immunotherapy improved survival of melanoma patients with leptomeningeal disease (LMD).
